Christine L. Chung
2021
Compensation breakdown
| Non-Equity Incentive Plan | $180,707 |
|---|---|
| Option Awards | $2,031,863 |
| Salary | $490,000 |
| Stock Awards | $1,688,225 |
| Other | $336,349 |
| Total | $4,727,144 |
Chung received $2M in option awards, accounting for 43% of the total pay in 2021.
Chung also received $180.7K in non-equity incentive plan, $490K in salary, $1.7M in stock awards and $336.3K in other compensation.
Rankings
In 2021, Christine L. Chung's compensation ranked 2,794th out of 12,406 executives tracked by ExecPay. In other words, Chung earned more than 77.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,794 out of 12,406 | 78th |
Division Manufacturing | 1,105 out of 5,494 | 80th |
Major group Chemicals And Allied Products | 436 out of 2,369 | 82nd |
Industry group Drugs | 380 out of 2,090 | 82nd |
Industry Pharmaceutical Preparations | 254 out of 1,537 | 84th |
Pay ratio
| Christine L. Chung's Pay | $4,727,144 |
|---|---|
| Median Employee's Pay | $174,414 |
| Pay Ratio | 27to 1 |
In 2021, the annual total compensation of Christine L. Chung was $4,727,144.
The annual total compensation of the median employee at FibroGen was $174,414.
The ratio of Christine L. Chung's pay to the pay of median employee was therefore 27 to one.
Chung's colleagues
We found six more compensation records of executives who worked with Christine L. Chung at FibroGen in 2021.
2021
Enrique Conterno
FibroGen
Chief Executive Officer
2021
Mark Eisner
FibroGen
Chief Medical Officer
2021
Pat Cotroneo
FibroGen
Chief Financial Officer
2021
Elias Kouchakji
FibroGen
Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance
2021
Thane Wettig
FibroGen
Chief Commercial Officer
2021
Juan Graham
FibroGen